Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cocrystal Pharma ( (COCP) ) has issued an announcement.
On January 9, 2026, Cocrystal Pharma’s Compensation Committee approved grants of non-qualified stock options to its directors, executive officers and a consultant under the company’s 2025 Equity Incentive Plan, with a 10-year term, an exercise price set at the January 8, 2026 closing price, and a vesting schedule that begins with half the options vesting on January 9, 2027 and the remainder vesting in eight equal quarterly installments starting March 31, 2027, contingent on continued service. The awards allocated varying numbers of options to board members, senior executives and a consultant and included a separate $50,000 cash award to Dr. Roger Kornberg for his role as chairman of the Scientific Advisory Board, underscoring the company’s emphasis on long-term equity-based incentives and recognition of scientific leadership in its governance and compensation strategy.
The most recent analyst rating on (COCP) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn, shrinking equity base). Technicals also remain bearish with the stock below major moving averages, while positive corporate milestones (trial initiation steps, NIH funding, and insider financing) provide partial offset but do not fully mitigate the fundamental funding and execution risks.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. operates in the biopharmaceutical industry, focusing on the discovery and development of antiviral therapeutics. The company’s work centers on designing and advancing small-molecule antiviral drugs targeting a range of viral diseases, positioning it within the specialty pharmaceutical and drug development market.
Average Trading Volume: 111,620
Technical Sentiment Signal: Strong Sell
Current Market Cap: $15.99M
For an in-depth examination of COCP stock, go to TipRanks’ Overview page.